Noninvasive Glucose Measurements - Database and Calibration Compilation

RSP Systems

Status: Terminated

Conditions: Diabetes

Treatments: Device: WM3.4

Study type: Interventional

Funder types: Industry

Identifiers

NCT03368209

RSP-07

Details and patient eligibility

About

This study collected spectral raman data from diabetic patients. Data was paired with validated capillary references as well as CGM/FGM readings. Data was used to develop models for glucose prediction.

Full description

This trial constitutes three subprotocols: "The OUH protocol", "The Home 1 protocol" and "The Home 2 protocol" The investigation was initiated to collect spectral raman data paired with validated blood references. In the OUH protocol, capillary blood was analysed by ABL 800 Flex blood gas analyzer by Radiometer. In the Home 1 protocol, references were obtained by the finger pricking procedure from HemoCue (Radiometer). In the Home 2 protocol, HemoCue measurements were conducted along with continuous monitoring using Dexcom G4/G5 device (Dexcom) or FreeStyle Libre (Abbott) The data was collected from diabetic patients and Optical Coherence Tomography (OCT) readings were obtained from all subjects.

Enrollment: 62 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects with and without diabetes including pregnant women

Exclusion criteria

• Subject under 18 years of age
• Subjects not able to understand provided information
• Subjects without measuring sites
• Subjects with rash or wound on measuring sites
• Subjects with stained fingers, such a oil or nicotine
• Subjects not capable of holding arm/hand steadily on probe
• Subjects with thrombosis in arm/hand

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

62 participants in 3 patient groups

OUH protocol

Experimental group

Description:

The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted: * Optical Coherence Tomography (OCT) * Optical screening on measuring site with WM3.4. Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2.

Treatment:

Device: WM3.4

Home 1 protocol

Experimental group

Description:

Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital. WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference.

Treatment:

Device: WM3.4

Home 2 protocol

Experimental group

Description:

Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital. WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference.

Treatment:

Device: WM3.4